BACKGROUND AND OBJECTIVES: To prevent graft-versus-host disease and rejection in hematopoietic cell transplantation (HCT), children receive Thymoglobulin(®), a polyclonal antibody acting mainly by depleting T cells. The therapeutic window is critical as over-exposure may result in delayed immune reconstitution of donor T cells. In this study, we describe the population pharmacokinetics of Thymoglobulin(®) as a first step towards an evidence-based dosing regimen of Thymoglobulin(®) in pediatric HCT. METHODS: Serum active Thymoglobulin(®) concentrations were measured in all pediatric HCTs performed between 2004 and 2012 in two pediatric HCT centers in The Netherlands. Population pharmacokinetic analysis was performed using NONMEM(®) version 7.2. RESULTS: A total of 3,113 concentration samples from 280 pediatric HCTs were analyzed, with age ranging from 3 months to 23 years old. The cumulative Thymoglobulin(®) dose was 10 mg/kg in 94 % of the patients given in 4 consecutive days. A model incorporating parallel linear and concentration-dependent clearance of Thymoglobulin(®) was identified. Body weight [for linear clearance (CL) and central volume of distribution] as well as lymphocyte count pre-Thymoglobulin(®) infusion (for CL) were important covariates. As such, the current dosing regimen results in higher exposure in children with a higher bodyweight and/or a lower lymphocyte count pre-Thymoglobulin(®) infusion. CONCLUSION: This model can be used to develop an individual dosing regimen for Thymoglobulin(®), based on both body weight and lymphocyte counts, once the therapeutic window has been determined. This individualized regimen may contribute to a better immune reconstitution and thus outcome of allogeneic HCT.
BACKGROUND AND OBJECTIVES: To prevent graft-versus-host disease and rejection in hematopoietic cell transplantation (HCT), children receive Thymoglobulin(®), a polyclonal antibody acting mainly by depleting T cells. The therapeutic window is critical as over-exposure may result in delayed immune reconstitution of donor T cells. In this study, we describe the population pharmacokinetics of Thymoglobulin(®) as a first step towards an evidence-based dosing regimen of Thymoglobulin(®) in pediatric HCT. METHODS: Serum active Thymoglobulin(®) concentrations were measured in all pediatric HCTs performed between 2004 and 2012 in two pediatric HCT centers in The Netherlands. Population pharmacokinetic analysis was performed using NONMEM(®) version 7.2. RESULTS: A total of 3,113 concentration samples from 280 pediatric HCTs were analyzed, with age ranging from 3 months to 23 years old. The cumulative Thymoglobulin(®) dose was 10 mg/kg in 94 % of the patients given in 4 consecutive days. A model incorporating parallel linear and concentration-dependent clearance of Thymoglobulin(®) was identified. Body weight [for linear clearance (CL) and central volume of distribution] as well as lymphocyte count pre-Thymoglobulin(®) infusion (for CL) were important covariates. As such, the current dosing regimen results in higher exposure in children with a higher bodyweight and/or a lower lymphocyte count pre-Thymoglobulin(®) infusion. CONCLUSION: This model can be used to develop an individual dosing regimen for Thymoglobulin(®), based on both body weight and lymphocyte counts, once the therapeutic window has been determined. This individualized regimen may contribute to a better immune reconstitution and thus outcome of allogeneic HCT.
Authors: Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Comput Methods Programs Biomed Date: 2010-06-02 Impact factor: 5.428
Authors: Elke H J Krekels; Johan G C van Hasselt; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe Journal: Pharm Res Date: 2010-12-14 Impact factor: 4.200
Authors: D R Mould; A Baumann; J Kuhlmann; M J Keating; S Weitman; P Hillmen; L R Brettman; S Reif; P L Bonate Journal: Br J Clin Pharmacol Date: 2007-05-16 Impact factor: 4.335
Authors: E H J Krekels; M Neely; E Panoilia; D Tibboel; E Capparelli; M Danhof; M Mirochnick; C A J Knibbe Journal: CPT Pharmacometrics Syst Pharmacol Date: 2012-10-03
Authors: Rosy Dabas; Kareem Jamani; Shahbal B Kangarloo; Poonam Dharmani-Khan; Tyler S Williamson; Samar Ousia; Caylib Durand; Don Morris; Douglas Mahoney; Lynn Savoie; Ahsan Chaudhry; Victor H Jimenez-Zepeda; Faisal M Khan; Andrew Daly; Jan Storek Journal: Blood Adv Date: 2019-05-14
Authors: Lisa V E Oostenbrink; Emma S Pool; Cornelia M Jol-van der Zijde; Anja M Jansen-Hoogendijk; Carly Vervat; Astrid G S van Halteren; Robbert G M Bredius; Frans J W Smiers; Maarten J D van Tol; Marco W Schilham; Arjan C Lankester; Alexander B Mohseny Journal: Bone Marrow Transplant Date: 2021-05-03 Impact factor: 5.483
Authors: R Admiraal; R Chiesa; C A Lindemans; S Nierkens; M B Bierings; A B Versluijs; P Hiwarkar; J M Furtado Silva; P Veys; J J Boelens Journal: Bone Marrow Transplant Date: 2016-05-09 Impact factor: 5.483
Authors: S H Lum; W P Miller; S Jones; K Poulton; W Ogden; H Lee; A Logan; D Bonney; T C Lund; P J Orchard; R F Wynn Journal: Bone Marrow Transplant Date: 2017-02-20 Impact factor: 5.483
Authors: J B Langenhorst; C van Kesteren; E M van Maarseveen; T P C Dorlo; S Nierkens; C A Lindemans; M A de Witte; A van Rhenen; R Raijmakers; M Bierings; J Kuball; A D R Huitema; J J Boelens Journal: Blood Adv Date: 2019-07-23
Authors: Michael Scordo; Valkal Bhatt; Patrick Hilden; Melody Smith; Katie Thoren; Christina Cho; Gunjan L Shah; Molly A Maloy; Esperanza B Papadopoulos; Ann A Jakubowski; Scott T Avecilla; Richard J O'Reilly; Hugo Castro-Malaspina; Roni Tamari; Brian C Shaffer; Jaap J Boelens; Miguel-Angel Perales; Sergio A Giralt Journal: Biol Blood Marrow Transplant Date: 2019-03-01 Impact factor: 5.742
Authors: Coco de Koning; Susan Prockop; Ichelle van Roessel; Nancy Kernan; Elizabeth Klein; Jurgen Langenhorst; Celina Szanto; Mirjam Belderbos; Marc Bierings; Farid Boulad; Dorine Bresters; Maria Cancio; Kevin Curran; Wouter Kollen; Richard O'Reilly; Andromachi Scaradavou; Barbara Spitzer; Birgitta Versluijs; Alwin Huitema; Caroline Lindemans; Stefan Nierkens; Jaap Jan Boelens Journal: Blood Date: 2021-02-11 Impact factor: 22.113